Multiomic profiling of human clonal hematopoiesis reveals genotype and cell-specific inflammatory pathway activation

J Brett Heimlich1, Pawan Bhat2, Alyssa C Parker2

  • 1Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.

Blood Advances
|March 20, 2024
PubMed

Insights

Clonal hematopoiesis (CH) increases risks for blood cancers and heart disease, driven by inflammation. This study reveals new inflammatory pathways in CH monocytes and impaired T-cell function in patients with CH.

Area of Science:

  • Hematology
  • Immunology
  • Genetics

Background:

  • Clonal hematopoiesis (CH) is linked to increased risks of hematologic malignancy and cardiovascular disease.
  • Inflammation in peripheral blood is a proposed mechanism driving CH-associated risks.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying CH-associated inflammation.
  • To compare gene expression profiles of mutant and non-mutant cells in CH patients.

Main Methods:

  • Single-cell RNA sequencing of peripheral blood from 17 CH patients and 7 controls.
  • Novel mitochondrial DNA barcoding to distinguish mutant (TET2, DNMT3A) and non-mutant cells.
  • Analysis of gene expression in myeloid and T-cell compartments.

Main Results:

  • The majority of mutated cells were identified in the myeloid compartment.
  • CH patients with DNMT3A/TET2 mutations showed a proinflammatory profile in CD14+ monocytes via galectin and macrophage inhibitory factor pathways.
  • T cells from CH patients exhibited decreased expression of immunity-associated GTPase genes, suggesting impaired T-cell function.

Conclusions:

  • CH is associated with distinct proinflammatory pathways in monocytes and impaired T-cell function.
  • These findings provide novel insights into CH pathogenesis and its systemic effects.
  • Targeting these pathways may offer therapeutic strategies for CH-related complications.

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
3.0K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K